This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tohda, H. Articles by Seiji, M. Search for Related Content PubMed PubMed Citation Articles by Tohda, H. Articles by Seiji, M.

A Convenient Method of Establishing Permanent Lines of Xeroderma Pigmentosum Cells¹

Department of Pharmacology, Research Institute for Tuberculosis and Cancer, Tohoku University, Sendai 980 [H. T., A. O.]; Department of Microbiology, Kumamoto University Medical School, Kumamoto 860 [T. K., Y. H.]; and Department of Dermatology, Tohoku University School of Medicine, Sendai 980 [M. S.], Japan

Nine lymphoblastoid cell lines were established after transformation by Epstein-Barr virus of peripheral lymphocytes from four xeroderma pigmentosum (XP) patients, the parents of one XP patient, and three normal donors. All these cell lines proliferate as suspensions in Roswell Park Memorial Institute Medium 1640 supplemented with 20% fetal bovine serum, without detectable release of infectious Epstein-Barr virus.

Some characteristics of these cell lines, such as growth rates, chromosome numbers, UV sensitivities, and activities of unscheduled DNA syntheses induced by UV, 4-nitroquinoline 1-oxide, and N-methyl-N'-nitro-N-nitrosoguanidine, were determined. Results confirm that the properties related to XP are not altered by transformation with Epstein-Barr virus and are the same in degrees of defect as are those of dermal fibroblasts from the respective individuals. These XP and normal lymphoblastoid cell lines should be especially useful for biochemical studies on the mechanism of DNA repair, because they are easy to grow in mass culture.

¹ This work was partly supported by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare and a grant from the Princess Takamatsu Cancer Research Fund.

Received 7/11/77. Accepted 10/24/77.